orthognathic surgery patients dexmedetomidine, blood loss, orthognathic surgery
Conditions
Interventions
Patients will receive intravenous dexmedetomidine bolus 1 mcg/kg in 10 minutes then infusion at a rate of 0.4 mcg/kg/hr intra-operation.,Patients will receive intravenous NSS as a placebo bolus 1 mcg/
Experimental Drug,Placebo Comparator No treatment
Sponsors
self support
Eligibility
Sex/Gender
All
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: 1. patient undergoing bimaxillary orthognathic surgery 2. ASA classification 1 or 2
Exclusion criteria
Exclusion criteria: 1. patient with coagulopathy 2. patient with bradycardia, cardiac dysrhythmias 3. known allergy to the study drugs 4. pregnancy and lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood loss, postoperative hemoglobin, blood transfusion the end of the operation intra-operative estimated blood loss, postoperative hemoglobin, incidence of blood transfusion | — |
Secondary
| Measure | Time frame |
|---|---|
| vital signs the end of operation Intra-operative heart rate, mean arterial pressure, and the amount of vasopressure usage,pain score, opioids requirement 24 hours after operation overall pain score, amount of opioid drug usage(intraoperative, postoperative in recovery room and in first 24 hr),operative time, quality of operative visual field, surgeons' satisfaction the end of operation operative time in minutes, Fromme's scale, Likert scale ,hospital stays, side effects the end of operation and 24 hours after operation episode of bradycardia, hypotension, arrhythmia and nausea/vomiting | — |
Countries
Thailand
Contacts
Public ContactThunshuda Sumphaongern
Faculty of Dentistry, Chulalongkorn university
Outcome results
None listed